Sarcopenia in Type 2 Diabetes Mellitus: A Cross-Sectional Observational Study

Background. The aim of this study was to compare the prevalence of low muscle mass and sarcopenia in patients with type 2 diabetes mellitus (T2DM) versus paired controls (control group, CG) and the association between sarcopenia and chronic diabetes complications. Methods. Men and women ≥50 years wi...

Full description

Saved in:
Bibliographic Details
Main Authors: L. M. Pechmann, T. H. Jonasson, V. S. Canossa, H. Trierweiler, G. Kisielewicz, R. R. Petterle, C. A. Moreira, V. Z. C. Borba
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2020/7841390
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832560143618801664
author L. M. Pechmann
T. H. Jonasson
V. S. Canossa
H. Trierweiler
G. Kisielewicz
R. R. Petterle
C. A. Moreira
V. Z. C. Borba
author_facet L. M. Pechmann
T. H. Jonasson
V. S. Canossa
H. Trierweiler
G. Kisielewicz
R. R. Petterle
C. A. Moreira
V. Z. C. Borba
author_sort L. M. Pechmann
collection DOAJ
description Background. The aim of this study was to compare the prevalence of low muscle mass and sarcopenia in patients with type 2 diabetes mellitus (T2DM) versus paired controls (control group, CG) and the association between sarcopenia and chronic diabetes complications. Methods. Men and women ≥50 years with T2DM (T2DM group, T2DMG) were recruited during routine outpatient visits. Total body densitometry and handgrip strength (HGS) were evaluated in the T2DMG and CG, while the T2DMG was also evaluated for the physical performance using the gait speed (GS) test. Sarcopenia was diagnosed according to the criteria of the Foundation for the National Institutes of Health Sarcopenia Project (FNIH). Results. The study included 177 individuals in the T2DMG and 146 in the CG. The mean HGS value was lower in the T2DMG (24.4 ± 10.3 kg) compared with the CG (30.9 ± 9.15 kg), p<0.001, with low HGS in 46 (25.9%) and 10 (9%) in the T2DMG and CG, respectively (p<0.001). The prevalence of sarcopenia defined according to the FNIH criteria was higher in the T2DMG 23 (12.9%) compared with the CG 8 (5.4%), p<0.03. The presence of albuminuria increased the odds of sarcopenia (odds ratio (OR) 2.84, 95% confidence interval (CI) 1.07–7.68, p=0.04) and osteoporosis (OR 3.38, 95% CI 1.12–9.89, p=0.03), even in patients with mild to moderate nephropathy. The body composition analysis showed increased odds of sarcopenia with increased percentage of total fat (%TF) in women (OR 1.18, 95% CI, 1.03–1.43, p=0.03) and men (OR 1.31, 95% CI, 1.10–1.75, p=0.01). Conclusion. Patients with T2DM presenting with albuminuria, osteoporosis, and increased %TF were more likely to have sarcopenia. This finding emphasizes the need for patients with T2DM to be evaluated for sarcopenia to allow for early implementation of measures to prevent or treat this disorder.
format Article
id doaj-art-d675d6631f294a199370fb1128b8dd60
institution Kabale University
issn 1687-8337
1687-8345
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series International Journal of Endocrinology
spelling doaj-art-d675d6631f294a199370fb1128b8dd602025-02-03T01:28:25ZengWileyInternational Journal of Endocrinology1687-83371687-83452020-01-01202010.1155/2020/78413907841390Sarcopenia in Type 2 Diabetes Mellitus: A Cross-Sectional Observational StudyL. M. Pechmann0T. H. Jonasson1V. S. Canossa2H. Trierweiler3G. Kisielewicz4R. R. Petterle5C. A. Moreira6V. Z. C. Borba7Internal Medicine and Endocrine Division (SEMPR), Universidade Federal do Paraná, Centro de Diabetes Curitiba, Curitiba, PR, BrazilEndocrine Division, Hospital de Clínicas da Universidade Federal Do Paraná (SEMPR), Avenida Agostinho Leão Júnior, 285, Alto da Glória, Curitiba, PR 80030-110, BrazilUniversidade Federal do Paraná, Curitiba, PR, BrazilUniversidade Federal do Paraná, Curitiba, PR, BrazilUniversidade Federal do Paraná, Curitiba, PR, BrazilDepartment of Integrative Medicine, Federal University of Paraná, Curitiba, PR, BrazilEndocrine Division, Hospital de Clínicas da Universidade Federal Do Paraná (SEMPR), Avenida Agostinho Leão Júnior, 285, Alto da Glória, Curitiba, PR 80030-110, BrazilEndocrine Division, Hospital de Clínicas da Universidade Federal Do Paraná (SEMPR), Avenida Agostinho Leão Júnior, 285, Alto da Glória, Curitiba, PR 80030-110, BrazilBackground. The aim of this study was to compare the prevalence of low muscle mass and sarcopenia in patients with type 2 diabetes mellitus (T2DM) versus paired controls (control group, CG) and the association between sarcopenia and chronic diabetes complications. Methods. Men and women ≥50 years with T2DM (T2DM group, T2DMG) were recruited during routine outpatient visits. Total body densitometry and handgrip strength (HGS) were evaluated in the T2DMG and CG, while the T2DMG was also evaluated for the physical performance using the gait speed (GS) test. Sarcopenia was diagnosed according to the criteria of the Foundation for the National Institutes of Health Sarcopenia Project (FNIH). Results. The study included 177 individuals in the T2DMG and 146 in the CG. The mean HGS value was lower in the T2DMG (24.4 ± 10.3 kg) compared with the CG (30.9 ± 9.15 kg), p<0.001, with low HGS in 46 (25.9%) and 10 (9%) in the T2DMG and CG, respectively (p<0.001). The prevalence of sarcopenia defined according to the FNIH criteria was higher in the T2DMG 23 (12.9%) compared with the CG 8 (5.4%), p<0.03. The presence of albuminuria increased the odds of sarcopenia (odds ratio (OR) 2.84, 95% confidence interval (CI) 1.07–7.68, p=0.04) and osteoporosis (OR 3.38, 95% CI 1.12–9.89, p=0.03), even in patients with mild to moderate nephropathy. The body composition analysis showed increased odds of sarcopenia with increased percentage of total fat (%TF) in women (OR 1.18, 95% CI, 1.03–1.43, p=0.03) and men (OR 1.31, 95% CI, 1.10–1.75, p=0.01). Conclusion. Patients with T2DM presenting with albuminuria, osteoporosis, and increased %TF were more likely to have sarcopenia. This finding emphasizes the need for patients with T2DM to be evaluated for sarcopenia to allow for early implementation of measures to prevent or treat this disorder.http://dx.doi.org/10.1155/2020/7841390
spellingShingle L. M. Pechmann
T. H. Jonasson
V. S. Canossa
H. Trierweiler
G. Kisielewicz
R. R. Petterle
C. A. Moreira
V. Z. C. Borba
Sarcopenia in Type 2 Diabetes Mellitus: A Cross-Sectional Observational Study
International Journal of Endocrinology
title Sarcopenia in Type 2 Diabetes Mellitus: A Cross-Sectional Observational Study
title_full Sarcopenia in Type 2 Diabetes Mellitus: A Cross-Sectional Observational Study
title_fullStr Sarcopenia in Type 2 Diabetes Mellitus: A Cross-Sectional Observational Study
title_full_unstemmed Sarcopenia in Type 2 Diabetes Mellitus: A Cross-Sectional Observational Study
title_short Sarcopenia in Type 2 Diabetes Mellitus: A Cross-Sectional Observational Study
title_sort sarcopenia in type 2 diabetes mellitus a cross sectional observational study
url http://dx.doi.org/10.1155/2020/7841390
work_keys_str_mv AT lmpechmann sarcopeniaintype2diabetesmellitusacrosssectionalobservationalstudy
AT thjonasson sarcopeniaintype2diabetesmellitusacrosssectionalobservationalstudy
AT vscanossa sarcopeniaintype2diabetesmellitusacrosssectionalobservationalstudy
AT htrierweiler sarcopeniaintype2diabetesmellitusacrosssectionalobservationalstudy
AT gkisielewicz sarcopeniaintype2diabetesmellitusacrosssectionalobservationalstudy
AT rrpetterle sarcopeniaintype2diabetesmellitusacrosssectionalobservationalstudy
AT camoreira sarcopeniaintype2diabetesmellitusacrosssectionalobservationalstudy
AT vzcborba sarcopeniaintype2diabetesmellitusacrosssectionalobservationalstudy